364 completed, 247 recruiting, 173 unknown, 139 terminated. 754 Phase 1, 303 Phase 2, 68 Not applicable, 41 Early Phase 1, 7 Phase 4.
Follow Solid Tumor: new trials by email Literature Review of Solid Tumor trials Research Report on Solid Tumor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Targeting CD276 (B7-H3) Positive Solid Tumors by 4SCAR-276 4SCAR-276 - Solid Tumor | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 100 | 2027-06-01 | 2026-11-02 |
| A Phase 1/2 Trial Of Larotrectinib And Pembrolizumab In Patients With Solid Tumors Previously Treated With Immune Checkpoint Inhibitor Monotherapy Larotrectinib, Pembrolizumab - Solid Tumor | Phase 1 / Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 22 | 2027-03-01 | 2026-09-28 |
| Intratumoral Chlorine Dioxide Injection in Advanced Solid Tumors Chlorine Dioxide Injection 2% - Solid Tumor, Neoplasms | Phase 1 | Not yet recruiting | SunGlow Innovations LLC | 50 | 2027-03-01 | 2026-11-02 |
| Mirdametinib to Reduce the Size of Large/Giant Congenital Melanocytic Nevi in Children, Adolescents and Young Adults Mirdametinib - LGCMN, Large and Giant Congenital Melanocytic Nevi | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 15 | 2027-01-04 | 2026-10-29 |
| GD2/PSMA Bi-specific CAR-T Cell Therapy bi-4SCAR GD2/PSMA T cells - Solid Tumor | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 60 | 2026-12-31 | 2026-11-02 |
| Study on GD2 Positive Solid Tumors by 4SCAR-GD2 4SCAR-GD2 - Solid Tumor | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 10 | 2026-12-31 | 2026-10-30 |
| An Investigational Study of BON-106 in Adults With Advanced or Metastatic Solid Tumors BON-106 - Solid Tumor, Advanced Solid Tumor | Phase 1 | Not yet recruiting | BeOne Medicines | 96 | 2026-12-01 | 2026-10-26 |
| Comparing Radiotherapy Dose Strategies for Symptom Relief in Large Solid Tumors Homogeneous External-Beam Radiotherapy, 20 Gy in Five Fractions, Homogeneous External-Beam Radiotherapy, 25 Gy in Five Fractions, LATTICE Radiotherapy, 20 Gy With a Simultaneous Integrated Boost to 66.7 Gy in Five Fractions - Solid Tumor | Not applicable | Not yet recruiting | Affidea Nu-med Center of Oncological DIagnostics and Therapy | 426 | 2026-12-01 | 2026-11-02 |
| SumMET: Study of [225Ac]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-MET [225Ac]Ac-FL-261 - Solid Tumor, NSCLC | Phase 1 / Phase 2 | Recruiting | Full-Life Technologies UK Limited | 208 | 2026-12-01 | 2026-11-16 |
| NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rare Solid Tumors Natural history study of individuals with very rare tumors - Very Rare Tumors, Very Rare Cancers | Recruiting | National Cancer Institute (NCI) | 4000 | 2026-11-24 | 2026-11-19 | |
| A Phase Ib/II Study of BM230 in Combination With PD-1 Inhibitor for HER2-related Advanced Solid Tumors BM230 & PD-1 inhibitor - Solid Tumor | Phase 1 / Phase 2 | Not yet recruiting | Suzhou Biomissile Pharmaceuticals Co., Ltd. | 90 | 2026-11-01 | 2026-10-09 |
| Validation of the G8 Screening Tool for Prognostic Assessment of Frailty and Early Mortality in Elderly Individuals With Cancer: Prospective Cohort Study in Brazil Solid Tumor, Metastatic Solid Tumor | Recruiting | Latin American Cooperative Oncology Group | 250 | 2026-11-01 | 2026-11-13 | |
| A Study of HRS-8046 in Patients With Advanced Solid Tumors: Safety, Tolerability, and Pharmacokinetics HRS-8046 Tablet - Solid Tumor | Phase 1 | Not yet recruiting | Chengdu Suncadia Medicine Co., Ltd. | 175 | 2026-11-01 | 2026-11-16 |
| A Clinical Trial on the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-9308 Tablet as Monotherapy or Combination Therapy in Participants With Advanced Solid Tumors HRS-9308 Tablet - Solid Tumor | Phase 1 / Phase 2 | Not yet recruiting | Chengdu Suncadia Medicine Co., Ltd. | 126 | 2026-11-01 | 2026-11-16 |
| A Study of Tagmokitug in Combination With Other Treatments in Participants With Advanced or Metastatic Solid Tumors Tagmokitug, Pasritamig - Solid Tumor | Phase 1 / Phase 2 | Recruiting | Coherus Oncology, Inc. | 12 | 2026-11-01 | 2026-11-18 |
| A Clinical Study of SHR-4595 Injection in Patients With Advanced Solid Tumors to Evaluate Safety, Tolerability and Pharmacokinetics SHR-4595 for Injection - Solid Tumor | Phase 1 | Recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 208 | 2026-10-20 | 2026-11-02 |
| A Study of DS-3939a in Participants With Solid Tumors DS-3939a, Pembrolizumab, Carboplatin - Solid Tumor, Locally Advanced Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Daiichi Sankyo | 400 | 2026-10-13 | 2026-11-10 |
| Proton and Proton-Photon Hybrid Partial Stereotactic Ablative Boost Radiotherapy (P-SABR) for Unresectable Large Tumors Proton P-SABR, Proton-Photon Hybrid P-SABR - Unresectable Malignant Neoplasm, Bulky Tumor | Not yet recruiting | Peking University First Hospital | 60 | 2026-10-01 | 2026-09-14 | |
| Clinical Study of Tumor Polypeptide DC-CTL in the Treatment of Solid Tumors Tumor polypeptide pool induced DC-CTL cell injection - Solid Tumor | Not applicable | Not yet recruiting | Zhengzhou Revo-Gene Technology Co., LTD | 20 | 2026-10-01 | 2026-09-02 |
| Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations ASKC189 - Solid Tumor, RAS Mutation | Phase 1 | Not yet recruiting | Jiangsu Aosaikang Pharmaceutical Co., Ltd. | 200 | 2026-09-30 | 2026-09-23 |
Showing 20 of 1072. Sign in to see all of them.
Neoplasms (151) · Neoplasm Metastasis (101) · Carcinoma, Non-Small-Cell Lung (90) · Colorectal Neoplasms (75) · Breast Neoplasms (71) · Lymphoma (57) · Melanoma (56) · Stomach Neoplasms (54) · Ovarian Neoplasms (49) · Pancreatic Neoplasms (48) · Hematologic Neoplasms (46) · Lung Neoplasms (37) · Squamous Cell Carcinoma of Head and Neck (34) · Endometrial Neoplasms (33) · Carcinoma, Renal Cell (28)
Neoplasms (417) · Neoplasms by Site (379) · Neoplasms by Histologic Type (250) · Digestive System Diseases (165) · Digestive System Neoplasms (161) · Neoplasms, Glandular and Epithelial (142) · Pathological Conditions, Signs and Symptoms (139) · Respiratory Tract Diseases (136) · Gastrointestinal Diseases (134) · Skin and Connective Tissue Diseases (134) · Lung Diseases (133) · Skin Diseases (133) · Hemic and Lymphatic Diseases (131) · Pathologic Processes (128) · Thoracic Neoplasms (127)
pembrolizumab (66) · Nivolumab (39) · Paclitaxel (27) · Cisplatin (24) · Gemcitabine (23) · Capecitabine (21) · Docetaxel (21) · Bevacizumab (18) · Cyclophosphamide (18) · Fluorouracil (18) · Injections (18) · atezolizumab (17) · Carboplatin (14) · Irinotecan (13) · fludarabine (13)
Sichuan Baili Pharmaceutical Co., Ltd. (25) · Eli Lilly and Company (20) · Jiangsu HengRui Medicine Co., Ltd. (15) · Memorial Sloan Kettering Cancer Center (14) · M.D. Anderson Cancer Center (11) · Merck Sharp & Dohme LLC (10) · Vanderbilt-Ingram Cancer Center (10) · Chinese PLA General Hospital (9) · Dana-Farber Cancer Institute (9) · Genentech, Inc. (9) · Impact Therapeutics, Inc. (9) · St. Jude Children's Research Hospital (9) · Peking University Cancer Hospital & Institute (8) · Athenex, Inc. (7) · Hoffmann-La Roche (7)
United States (491) · China (325) · France (78) · South Korea (70) · Spain (69) · Australia (61) · Canada (47) · United Kingdom (47) · Japan (43) · Belgium (30) · Italy (30) · Netherlands (30) · Taiwan (27) · Germany (23) · Denmark (17)
David Cutler, MD (5) · Jian Zhang (4) · Anna Spreafico, MD (3) · Barbara A. Murphy, MD (3) · Chuanling Li (3)
PMID 38172595, PMID 29505699, PMID 31401903, PMID 35101941, PMID 37082579, PMID 37592303, PMID 42109657, PMID 42413526, PMID 42636835, PMID 12637481, PMID 16575919, PMID 17244780, PMID 18463792, PMID 19139178, PMID 20305636, PMID 21601826, PMID 21739119, PMID 21810918, PMID 22382879, PMID 22415795, PMID 23615181, PMID 24173967, PMID 24349470, PMID 24477603, PMID 24523121, PMID 24819685, PMID 25086465, PMID 25287830, PMID 25380636, PMID 26095785, PMID 26172205, PMID 26222558, PMID 26390038, PMID 26600474, PMID 26808671, PMID 26836990, PMID 26942463, PMID 26966027, PMID 26984445, PMID 26984449, PMID 27000274, PMID 27053773, PMID 27138582, PMID 27157491, PMID 27240885, PMID 27247226, PMID 27565932, PMID 27627808, PMID 27646946, PMID 27871319
2023 (15), 2018 (10), 2019 (8), 2016 (7), 2015 (6), 2014 (5), 2017 (3), 2008 (2), 2025 (1), K08CA279500 (1), K12CA167540 (1), P01CA111412 (1), P30CA012197 (1), P30CA016059 (1), P30CA068485 (1)